Blue Matter is a consulting firm serving the life sciences industry. We strive to bring a new approach to consulting with original ideas that deliver a meaningful impact.
We are proud to be part of an industry that is pushing the boundaries of science and technology to improve people’s lives. Our role is to help our clients identify unique insights, generate new ideas and drive meaningful results to get the most out of their products, portfolios and teams.
We began our careers in established consulting firms where we developed valuable experience and industry knowledge. During this time, we came to see that rigid processes often interfered with original thinking and led to bloated deliverables packed with mediocre answers.
A group of us like-minded, passionate consultants believed there was a better approach and founded Blue Matter to provide a platform to foster innovation and creativity in consulting.
Industry and scientific knowledge, analysis and insights. Left brain thinking. This is the foundation of our discipline. Creativity and imagination. Constantly challenging conventional thinking and seeking fresh ideas. Right brain thinking. We’re passionate about this; it’s the reason our clients come back.
The key to winning is effective differentiation. And effective differentiation comes from originality–thinking that is grounded in reason and infused with imagination.
"The terrific work you did resulted in a substantial change to our commercial strategy."
- Chairman of the Board, Small Biotech
"Thank you very much for the great work and partnership. You are one of the rare breed of consultants whom I trust. You will always be on my speed dial if we need help with anything."
- Chief Commercial Officer, Small Biotech
"I appreciate all of the great work you have done for our team this past year and look forward to continued partnership in the New Year."
- Chief Commercial Officer, Mid-sized Diagnostic Company
"Your preparation and support has been instrumental in achieving our desired outcome."
- Franchise Commercial Lead, Global Biotech
"Thank you all so much for the extremely successful project...I couldn't be happier with the way that it went."
- Sr. Product Manager, Diagnostic Company
"This project was excellent, from the content development to facilitation. Many, many thanks for the great work!"
- Director of Marketing, Diagnostic Company
"The process was great, I loved that I didn't have to manage you that much. Everything was highly organized and done on time. Quality and originality of thinking was also good."
- Global Commercial Lead, Large Biotech
"Great project. I was learning as we went along; good expertise — brought in examples from other projects."
- Global Commercial Lead, Large Biotech
Our clients include: top global bio-pharmaceutical companies with large, diverse product portfolios to small emerging players with one asset in development, leading diagnostic companies, and investment houses. We work with CEOs, Chief Commercial Officers, Franchise Heads, Product Directors, Functional Area Leaders. 90%+ of our business is from repeat, satisfied customers.
Shape Innovative Products
- New Product Development & Commercialization
Case Study: Designed to Win
Drive Successful Launches
- Global, Regional and Local Launch Strategy & Planning
Case Study: Flawless Launch
- Brand & Lifecycle Planning
Case Study: Peak Performance
July Oncology News Roundup
Key events from the world of oncology
Blue Matter Consulting is tracking oncology market trends on a daily basis, and looks back each month to highlight the newsworthy events shaping our current and future oncology market landscape.
Crucial Astra Zeneca IO study fails to show clinical benefit..Read More
FDA CAR-T ODAC Hearing: Key Takeaways
The ODAC hearing on Novartis’ breakthrough CAR-T therapy, tisagenlecleucel, was overwhelmingly positive, as the Committee unanimously recommended approval of the therapy for relapsed or refractory pediatric and young adult patients with b-cell ALL. The hearing paved the way for an efficient regulatory approval of Novartis’ CAR-T therapy, and also provided insight into opportunities for future CAR-T therapies to more directly address lingering issues raised in the ODAC sessionRead More
Clinical Implications of ASCO'17
ASCO 2017 met high expectations and delivered a plethora of exciting data. The conference showcased data on promising new molecular targets, combination regimens, and delivery mechanisms in development, and provided valuable insights that will impact current use of commercially available therapiesRead More
Are We at a Tipping Point for Gene Therapy?
Thirty years after the earliest gene therapies were tested in patients, the promise of this potentially revolutionary class of medicine is now close to fruition. Gene therapy, or the delivery of nucleic acids to cells in order to address diseases linked to genetic mutations, is at the most significant crossroads in its long journey to market. As the gene therapy market matures from experimental to commercial, the question facing physicians, patients, researchers, and investors is—will gene therapy overcome its bumpy three-decade road to market to be the next game-changing medical innovation?Read Full Entry
Highlights from ASH 2016
The American Society of Hematology, a 58-year-old organization of hematologists, wrapped up its 2016 annual meeting in San Diego this week. The conference features many of the biggest names in the pharmaceutical and biotech industries and serves as a platform to announce new drugs, clinical trial results and initiatives for the future. ASH 2016 was the biggest meeting ever and is the largest hematology meeting in the world, with over 27,000 in attendance this week.
Some of the key data highlights of ASH 2016 are outlined here.Read Full Entry
A Rising Tide (in Early-stage Research) Lifts All Boats?
Given the average cost and time it takes to successfully bring a drug to market ($1 billion, and 10 years), it’s not surprising that pharmaceutical companies have sought to de-risk their R&D portfolios by acquiring later stage, more clinically-advanced molecules. However, The Accelerating Medicines Partnership (AMP), a collaboration between the NIH and 10 drug companies (including several top 10 global competitors), is aimed squarely at the opposite approach – identifying disease areas with high unmet need and then systematically supporting early stage research collaboratively: with funding, scientists, and oversight from both academic and industry partners.Read Full Entry